Company intelligence / Profile preview

Viome

Bellevue, Washington, United Statesviome.com ↗

Ownership: Private
Employees: ~95
Development stage: Commercial

Overview

Viome has commercialized at-home testing kits that use RNA sequencing to analyze the human microbiome and host gene expression. Their platform provides personalized food and supplement recommendations based on real-time biological data. The company has sold over 500,000 kits and launched early-stage diagnostic products for oral/throat cancer risk assessment. Clinical research includes both observational studies with large cohorts (>300k samples) and interventional trials for product validation

Therapeutic areas: OtherOncology
Modalities: Live biotherapeutic product therapyMicrobial therapyDevice (diagnostic)Small molecule (supplements/nutrients)
Industry: Molecular Diagnostics

Partnerships

Not explicitly listed; notable investors include Salesforce CEO Marc Benioff and Khosla Ventures

Beyond the preview

Go deeper on Viome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viome.

Explore the full profile